drugset / Trial / NCT02145377
PXVX0200 (CVD103-HgR) vs Shanchol in Mali
Phase 2
Completed
150 enrolled
University of Maryland, Baltimore
Emergent BioSolutions · collabShantha Biotechnics Limited · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
To compare the ability of a single dose of PXVX0200 at two different dose levels, to placebo to elicit a significant antibody response 14 days after vaccination, compared to baseline. To compare the ability of a single dose of PXVX0200 to a comparator vaccine Shanchol, a two dose administration, to elicit antibody response by 14 days after vaccination.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PXVX0200 | Vaccine | 1e+08 unknown | Oral |
| Subject | PXVX0200 | Vaccine | 1e+09 unknown | Oral |
| Comparator | Shanchol | Vaccine | — | Oral |